Therapy News and Research

RSS

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

New amplitude gating technique helps scanners pinpoint tumors

When one diagnoses a cancer patient, it's important to gather as much information about that person as possible. But who would have thought an accurate diagnosis would depend on throwing some of that information away?

12 Feb 2010

New screening system developed to discover molecules that block HCV life cycle

A newly designed system of identifying molecules for treating hepatitis C should enable scientists to discover novel and effective therapies for the dangerous and difficult-to-cure disease of the liver, says Zhilei Chen, a Texas A&M University assistant professor of chemical engineering who helped develop the screening system.

12 Feb 2010

Biological-based therapies are alternative medicines for women recovering from breast cancer

Biological-based therapies such as diet supplements and vitamins are the most popular complementary and alternative medicines for women recovering from breast cancer, according to a Michigan State University researcher working to create a support intervention for women in treatment for the disease.

12 Feb 2010

FKF receives funds to launch Fragile Kids Partner Program

The Centene Foundation for Quality Healthcare announced today that it has awarded a $35,000 grant to Fragile Kids Foundation, Inc. (FKF), a nonprofit organization based in Atlanta, Ga.

12 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

Decline in breast cancer rates linked to race, ethnicity and economic background

Breast cancer rates are declining, but some groups have seen a more significant decline than others, with race, ethnicity and economic background playing a part.

11 Feb 2010

Cognitive behavioral therapy effective for insomnia and chronic pain

Cognitive behavioral therapy for insomnia significantly improved sleep for patients with chronic neck or back pain and also reduced the extent to which pain interfered with their daily functioning, according to a study by University of Rochester Medical Center researchers.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

$NovaShunt initiates study to evaluate AFS for refractory ascites patients$

NovaShunt initiates study to evaluate AFS for refractory ascites patients

NovaShunt today announced the initiation of its pivotal multi- center clinical study named PIONEER, a Prospective, multi-center, open label, non-randomized study to Investigate the safety and perfOrmance of the Automated Fluid ShuNt in patiEnts with ascitEs and diuretic Resistance.

11 Feb 2010

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

Cancer Research UK scientists have identified the frequency of new genetic 'hotspots' which could help doctors to tailor therapies to as many as 3,000 additional bowel cancer patients each year, according to research published in the British Journal of Cancer today.

11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

C. R. Bard, Inc. today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access grafts more effectively than balloon angioplasty alone. The FLAIR® Endovascular Stent Graft is the only implant approved by the U.S. Food and Drug Administration for use in the treatment of stenoses at the venous anastomosis of ePTFE or other synthetic arteriovenous access grafts.

11 Feb 2010

New research solves mystery behind speech disorder

The mystery behind a complex disorder called stuttering became a little clearer today with the announcement of the discovery of three genes for stuttering by Dennis Drayna, Ph.D., a director of the Stuttering Foundation and researcher for the National Institute on Deafness and Other Communication Disorders.

11 Feb 2010

People with GAD have abnormalities in the way their brain unconsciously controls emotions

People with generalized anxiety disorder, or GAD, have abnormalities in the way their brain unconsciously controls emotions. That's the conclusion of a new Stanford University School of Medicine study, and the study authors say the findings could open up new avenues for treatments and change our understanding of how emotion is regulated in everyday life.

11 Feb 2010

Boston Scientific rebuts HeartRhythm's cardiac resynchronization therapy defibrillator implantation article

Boston Scientific Corporation today rebutted an article published in the journal HeartRhythm. The article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator. The article suggested a weakened header bond was responsible for the abnormal sensing and pacing impedance experienced by the patient.

11 Feb 2010

Findings could lead to new targeted therapies for speech and learning disabilities

A team of University of Oregon researchers have isolated an independent processing channel of synapses inside the brain's auditory cortex that deals specifically with shutting off sound processing at appropriate times.

11 Feb 2010

Therapy News and Research

Second-quarter fiscal 2010 results announced by Pharmacyclics

Cancer drug could be effective for treating recurrent nose bleeds

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

New amplitude gating technique helps scanners pinpoint tumors

New screening system developed to discover molecules that block HCV life cycle

Biological-based therapies are alternative medicines for women recovering from breast cancer

FKF receives funds to launch Fragile Kids Partner Program

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Decline in breast cancer rates linked to race, ethnicity and economic background

Cognitive behavioral therapy effective for insomnia and chronic pain

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

NovaShunt initiates study to evaluate AFS for refractory ascites patients

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

Bard FLAIR Endovascular Stent Graft more effective than balloon angioplasty for failing dialysis grafts

New research solves mystery behind speech disorder

People with GAD have abnormalities in the way their brain unconsciously controls emotions

Boston Scientific rebuts HeartRhythm's cardiac resynchronization therapy defibrillator implantation article

Findings could lead to new targeted therapies for speech and learning disabilities

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News